The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections

Digestive Diseases and Sciences

Volumn 53, Issue 5, 2008, Pages 1375-1382

  Sterling, Richard K ^a,c   Chiu, Steven ^b   Snider, Kenny ^c   Nixon, Daniel ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Abnormal liver enzymes; HIV infection

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LIVER ENZYME; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE DENSITY; FATTY LIVER; FEMALE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LIVER FUNCTION TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT;

ADULT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; FEMALE; HEPATITIS B; HEPATITIS C; HIV SEROPOSITIVITY; HUMANS; LIVER; LIVER FUNCTION TESTS; LOGISTIC MODELS; MALE; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 41949140598     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-9999-6     Document Type: Article

References (40)

1. Lee LM, Karon JM, Selik R, Neal JJ, Fleming PL (2001) Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA 285(10):1308-1315
2. Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338(13):853-860
3. Pol S, Lebray P, Vallet-Pichard A (2004) HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis 38(Suppl 2):S65-S72
4. Sabin CA (2004) Pitfalls of assessing hepatotoxicity in trials and observational cohorts. Clin Infect Dis 38(Suppl 2):S56-S64
5. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD (2004) Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 18(17):2277-2284
6. Meraviglia P, Schiavini M, Castagna A, Vigano P, Bini T, Landonio S et al (2004) Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation. HIV Med 5(5):334-343
7. Kottilil S, Polis MA, Kovacs JA (2004) HIV Infection, hepatitis C infection, and HAART: hard clinical choices. JAMA 292(2):243-250
8. Armstrong GL, Wasley A, Simard EP, McQuillan GM et al (2006) The prevalence of hepatitis C virus infection in the United States, 1999-2002. Ann Intern Med 144:705-714
9. Rockstroh JK, Mocroft A, Soriano V, Tural C et al (2005) Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiviral therapy. J Infect Dis 192:992-1002
10. Maida I, Nunez M, Rios MJ, Martin-Carbonero L, Sotgiu G et al (2006) Severe liver disease associated with prolonged exposure to antiretroviral drugs. JAIDS 42:177-182
11. Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B et al (2003) Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 32(3):259-267
12. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD (2000) Elevated liver enzymes following initiation of antiretroviral therapy. JAMA 283(19):2526-2527
13. French AL, Benning L, Anastos K, Augenbraun M, Nowicki M, Sathasivam K et al (2004) Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection. Clin Infect Dis 39(3):402-410
14. Maddrey WC (2005) Drug-induced hepatoxicity. J Clin Gastroenterol 39(Suppl 2):S83-S89
15. Neff GW, Jayawerra D, Sherman KE (2006) Drug-induced liver injury in HIV patients. Gastroenterol Hepatol 2:430-437
16. Pantsari MW, Harrison SA (2006) Nonalcoholic fatty liver disase presenting with an isolated elevated alkaline phosphatase. J Clin Gastroenterol 40:633-635
17. Bjornsson E, Olsson R (2005) Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 42:481-489
18. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, Garcia-Munoz B, Gonzalez-Grande R et al (2005) Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology 129:512-521
19. Ioannou GN, Weiss NS, Boyko EJ, Kahn SE, Lee SP (2005) Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology 128:627-635
20. Rodriguez-Rosado R, Perez-Olmeda M, Garcia-Samaniego J, Soriano V (2001) Management of hepatitis C in HIV-infected persons. Antiviral Res 52(2):189-198
21. Carr A (2000) HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 30(Suppl 2):S135-S142
22. Hui DY (2003) Effects of protease inhibitor therapy on lipid metabolism. Prog Lipid Res 42:81-92
23. Carr A, Samaras K, Thorisdottir A, Kaufmann GR et al (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: a cohort study. Lancet 353:2093-2099
24. Stein JH (2003) Dyslipidemia in the era of HIV protease inhibitors. Prog Cardiovasc Dis 45:293-304
25. Tsiodras S, Mantzoros C, Hammer S, Samore M (2000) Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy. Arch Intern Med 160:2050-2056
26. Mulligan K, Grundfeld C, Tai VW, Algren H et al (2000) Hyperlipidemia and insulin rsistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. JAIDS 23:35-43
27. Nolan D, Mallal S (2001) Getting to the HAART of insulin resistance. AIDS 15(15):2037-2041
28. Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD et al (2005) Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 19(6):585-592
29. Bani-Sadr F, Carrat F, Bedossa P, Piroth L et al (2006) Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS 20:525-531
30. Kakuda TN (2000) Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22:685-708
31. Benhamou Y, Di MV, Bochet M, Colombet G, Thibault V, Liou A et al (2001) Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 34(2):283-287
32. Macias J, Castellano V, Merchante N, Palacios RB, Mira JA et al (2004) Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 18:767-774
33. Zhou H, Gurley EC, Jarujaron S, Ding H, Fang Y, Xu Z, Pandak WM, Hyleman PB (2006). HIV protease inhibitors activate the unfolded protein response, disrupt lipid metabolism in primary hepatocytes. Am J Physiol Gastrointest Liver Physiol. doi: 10.1152/ajpgi.00182.2006
34. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ (2003) Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37:1286-1292
35. Sánchez-Conde M, Berenguer J, Miralles P, Alvarez F, Carlos Lopez J, Cosin J, Pilar C, Ramírez M, Gutierrez I, Alvarez E (2006) Liver biopsy findings for HIV-infected patients with chronic hepatitis c and persistently normal levels of alanine aminotransferase. Clin Infect Dis 43:640-644
36. Urial A, Moorehead L, Agarwal K et al (2005). Insulin resistance associated with poorer HCV virologic response in HCV/HIV coinfected patients. Program and abstracts of the 12th conference on retroviruses and opportunistic infections, Boston, MA, February 22-25, 2005, Abstract 925
37. Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL (2005) Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology 42(2):310-316
38. Marks KM, Petrovic LM, Talal AH, Murray MP et al (2005) Histologic findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis 192:1943-1949
39. Lapoile E, Vona G, Canioni D, Chaix M-L, Nalpas B, Fontaine C et al (2002). Factors participating in severe HCV-related liver disease in HIV/HCV coinfection. J Hepatol 36(Suppl 1):172 (Abstract 609)
40. Wanless IR, Lentz JS (1990) Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12(5):1106-1110